MedTrace Logo

Predictors of Persistence in Patients With Schizophrenia Treated With Once-monthly Aripiprazole in Spain

NCT03130478 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 119

Last updated 2018-08-21

No results posted yet for this study

Summary

This is an observational, retrospective, non-interventional study that will include schizophrenic patients who were initiated on AOM treatment during an schizophrenia-related hospitalisation at least 6 months before data collection and in a real clinical practice setting.

Conditions

Sponsors & Collaborators

  • Otsuka Pharmaceutical Europe Ltd

    lead INDUSTRY

Principal Investigators

  • Medical Department · Otsuka Europe

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-18
Primary Completion
2018-07-30
Completion
2018-07-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03130478 on ClinicalTrials.gov